Familial gastric cancer: overview and guidelines for management.
PDF (100K)
+19 authors
Journal: 2000/January - Journal of Medical Genetics
ISSN: 0022-2593
PUBMED: 10593993
Abstract:
Families with autosomal dominant inherited predisposition to gastric cancer have been described. More recently, germline E-cadherin/CDH1 mutations have been identified in hereditary diffuse gastric cancer kindred. The need to have protocols to manage and counsel these families in the clinic led a group of geneticists, gastroenterologists, surgeons, oncologists, pathologists, and molecular biologists to convene a workshop to produce consensus statements and guidelines for familial gastric cancer. Review of the available cancer pathology from people belonging to families with documented germline E-cadherin/CDH1 mutations confirmed that the gastric cancers were all of the diffuse type. Criteria to define the different types of familial gastric cancer syndromes were agreed. Foremost among these criteria was that review of histopathology should be part of the evaluation of any family with aggregation of gastric cancer cases. Guidelines for genetic testing and counselling in hereditary diffuse gastric cancer were produced. Finally, a proposed strategy for clinical management in families with high penetrance autosomal dominant predisposition to gastric cancer was defined.
Open in
PUBMED | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(97)
References
(39)
Diseases
(1)
Conditions
(1)
Chemicals
(1)
Organisms
(1)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
J Med Genet 36(12): 873-880
PMID: 10593993

Familial gastric cancer: overview and guidelines for management*

+15 authors

Abstract

Families with autosomal dominant inherited predisposition to gastric cancer have been described. More recently, germline E-cadherin/CDH1 mutations have been identified in hereditary diffuse gastric cancer kindred. The need to have protocols to manage and counsel these families in the clinic led a group of geneticists, gastroenterologists, surgeons, oncologists, pathologists, and molecular biologists to convene a workshop to produce consensus statements and guidelines for familial gastric cancer. Review of the available cancer pathology from people belonging to families with documented germline E-cadherin/CDH1 mutations confirmed that the gastric cancers were all of the diffuse type. Criteria to define the different types of familial gastric cancer syndromes were agreed. Foremost among these criteria was that review of histopathology should be part of the evaluation of any family with aggregation of gastric cancer cases. Guidelines for genetic testing and counselling in hereditary diffuse gastric cancer were produced. Finally, a proposed strategy for clinical management in families with high penetrance autosomal dominant predisposition to gastric cancer was defined.


Keywords: gastric cancer; familial; hereditary; E-cadherin

Full Text

The Full Text of this article is available as a PDF (100K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Abulrahi HA, Bohlega EA, Fontaine RE, al-Seghayer SM, al-Ruwais AA. Plasmodium falciparum malaria transmitted in hospital through heparin locks. Lancet. 1997 Jan 4;349(9044):23–25. [PubMed] [Google Scholar]
  • Correa P, Chen VW. Gastric cancer. Cancer Surv. 1994;19-20:55–76. [PubMed] [Google Scholar]
  • Bonney GE, Elston RC, Correa P, Haenszel W, Zavala DE, Zarama G, Collazos T, Cuello C. Genetic etiology of gastric carcinoma: I. Chronic atrophic gastritis. Genet Epidemiol. 1986;3(4):213–224. [PubMed] [Google Scholar]
  • JONES EG. FAMILIAL GASTRIC CANCER. N Z Med J. 1964 May;63:287–296. [PubMed] [Google Scholar]
  • Seruca R, Carneiro F, Castedo S, David L, Lopes C, Sobrinho-Simões M. Familial gastric polyposis revisited. Autosomal dominant inheritance confirmed. Cancer Genet Cytogenet. 1991 May;53(1):97–100. [PubMed] [Google Scholar]
  • Shafiuddin M, Caminker M, Batra S. Hereditary linitis plastica of the stomach. Am J Gastroenterol. 1995 Nov;90(11):2062–2063. [PubMed] [Google Scholar]
  • Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, Taite H, Scoular R, Miller A, Reeve AE. E-cadherin germline mutations in familial gastric cancer. Nature. 1998 Mar 26;392(6674):402–405. [PubMed] [Google Scholar]
  • LAUREN P. THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. Acta Pathol Microbiol Scand. 1965;64:31–49. [PubMed] [Google Scholar]
  • Carneiro F, Seixas M, Sobrinho-Simões M. New elements for an updated classification of the carcinomas of the stomach. Pathol Res Pract. 1995 Jul;191(6):571–584. [PubMed] [Google Scholar]
  • Machado JC, Soares P, Carneiro F, Rocha A, Beck S, Blin N, Berx G, Sobrinho-Simões M. E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. Lab Invest. 1999 Apr;79(4):459–465. [PubMed] [Google Scholar]
  • Becker KF, Atkinson MJ, Reich U, Becker I, Nekarda H, Siewert JR, Höfler H. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res. 1994 Jul 15;54(14):3845–3852. [PubMed] [Google Scholar]
  • Tamura G, Sakata K, Nishizuka S, Maesawa C, Suzuki Y, Iwaya T, Terashima M, Saito K, Satodate R. Inactivation of the E-cadherin gene in primary gastric carcinomas and gastric carcinoma cell lines. Jpn J Cancer Res. 1996 Nov;87(11):1153–1159.[PMC free article] [PubMed] [Google Scholar]
  • Muta H, Noguchi M, Kanai Y, Ochiai A, Nawata H, Hirohashi S. E-cadherin gene mutations in signet ring cell carcinoma of the stomach. Jpn J Cancer Res. 1996 Aug;87(8):843–848.[PMC free article] [PubMed] [Google Scholar]
  • Carneiro F, Santos L, David L, Dabelsteen E, Clausen H, Sobrinho-Simões M. T (Thomsen-Friedenreich) antigen and other simple mucin-type carbohydrate antigens in precursor lesions of gastric carcinoma. Histopathology. 1994 Feb;24(2):105–113. [PubMed] [Google Scholar]
  • Palli D, Galli M, Caporaso NE, Cipriani F, Decarli A, Saieva C, Fraumeni JF, Jr, Buiatti E. Family history and risk of stomach cancer in Italy. Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):15–18. [PubMed] [Google Scholar]
  • Gayther SA, Gorringe KL, Ramus SJ, Huntsman D, Roviello F, Grehan N, Machado JC, Pinto E, Seruca R, Halling K, et al. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res. 1998 Sep 15;58(18):4086–4089. [PubMed] [Google Scholar]
  • Richards FM, McKee SA, Rajpar MH, Cole TR, Evans DG, Jankowski JA, McKeown C, Sanders DS, Maher ER. Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet. 1999 Apr;8(4):607–610. [PubMed] [Google Scholar]
  • Guilford PJ, Hopkins JB, Grady WM, Markowitz SD, Willis J, Lynch H, Rajput A, Wiesner GL, Lindor NM, Burgart LJ, et al. E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Hum Mutat. 1999;14(3):249–255. [PubMed] [Google Scholar]
  • Keller G, Vogelsang H, Becker I, Hutter J, Ott K, Candidus S, Grundei T, Becker KF, Mueller J, Siewert JR, et al. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol. 1999 Aug;155(2):337–342.[PMC free article] [PubMed] [Google Scholar]
  • Shinmura K, Kohno T, Takahashi M, Sasaki A, Ochiai A, Guilford P, Hunter A, Reeve AE, Sugimura H, Yamaguchi N, et al. Familial gastric cancer: clinicopathological characteristics, RER phenotype and germline p53 and E-cadherin mutations. Carcinogenesis. 1999 Jun;20(6):1127–1131. [PubMed] [Google Scholar]
  • Yoon KA, Ku JL, Yang HK, Kim WH, Park SY, Park JG. Germline mutations of E-cadherin gene in Korean familial gastric cancer patients. J Hum Genet. 1999;44(3):177–180. [PubMed] [Google Scholar]
  • Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG, Griffioen G, Nagengast FM, Meijers-Heijboer EH, Bertario L, Varesco L, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology. 1996 Apr;110(4):1020–1027. [PubMed] [Google Scholar]
  • Aarnio M, Salovaara R, Aaltonen LA, Mecklin JP, Järvinen HJ. Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome. Int J Cancer. 1997 Oct 21;74(5):551–555. [PubMed] [Google Scholar]
  • Lindor NM, Greene MH. The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst. 1998 Jul 15;90(14):1039–1071. [PubMed] [Google Scholar]
  • Varley JM, McGown G, Thorncroft M, Tricker KJ, Teare MD, Santibanez-Koref MF, Martin J, Birch JM, Evans DG. An extended Li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation in TP53. J Med Genet. 1995 Dec;32(12):942–945.[PMC free article] [PubMed] [Google Scholar]
  • Lynch HT, Krush AJ. Cancer family "G" revisited: 1895-1970. Cancer. 1971 Jun;27(6):1505–1511. [PubMed] [Google Scholar]
  • La Vecchia C, Negri E, Franceschi S, Gentile A. Family history and the risk of stomach and colorectal cancer. Cancer. 1992 Jul 1;70(1):50–55. [PubMed] [Google Scholar]
  • Berx G, Becker KF, Höfler H, van Roy F. Mutations of the human E-cadherin (CDH1) gene. Hum Mutat. 1998;12(4):226–237. [PubMed] [Google Scholar]
  • Wanebo HJ, Kennedy BJ, Chmiel J, Steele G, Jr, Winchester D, Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg. 1993 Nov;218(5):583–592.[PMC free article] [PubMed] [Google Scholar]
  • Yoshida S, Saito D. Gastric premalignancy and cancer screening in high-risk patients. Am J Gastroenterol. 1996 May;91(5):839–843. [PubMed] [Google Scholar]
  • Stepp H, Sroka R, Baumgartner R. Fluorescence endoscopy of gastrointestinal diseases: basic principles, techniques, and clinical experience. Endoscopy. 1998 May;30(4):379–386. [PubMed] [Google Scholar]
  • Fennerty MB. Should chromoscopy be part of the "proficient" endoscopist's armamentarium? Gastrointest Endosc. 1998 Mar;47(3):313–315. [PubMed] [Google Scholar]
  • Miholic J, Meyer HJ, Kotzerke J, Balks J, Aebert H, Jähne J, Weimann A, Pichlmayr R. Emptying of the gastric substitute after total gastrectomy. Jejunal interposition versus Roux-y esophagojejunostomy. Ann Surg. 1989 Aug;210(2):165–172.[PMC free article] [PubMed] [Google Scholar]
  • Miholic J, Meyer HJ, Müller MJ, Weimann A, Pichlmayr R. Nutritional consequences of total gastrectomy: the relationship between mode of reconstruction, postprandial symptoms, and body composition. Surgery. 1990 Sep;108(3):488–494. [PubMed] [Google Scholar]
  • Cuschieri A. Jejunal pouch reconstruction after total gastrectomy for cancer: experience in 29 patients. Br J Surg. 1990 Apr;77(4):421–424. [PubMed] [Google Scholar]
  • Svedlund J, Sullivan M, Liedman B, Lundell L, Sjödin I. Quality of life after gastrectomy for gastric carcinoma: controlled study of reconstructive procedures. World J Surg. 1997 May;21(4):422–433. [PubMed] [Google Scholar]
  • Liedman B, Andersson H, Bosaeus I, Hugosson I, Lundell L. Changes in body composition after gastrectomy: results of a controlled, prospective clinical trial. World J Surg. 1997 May;21(4):416–421. [PubMed] [Google Scholar]
  • Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJ, van de Vijver M, Cornelisse C, van Roy F. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J. 1995 Dec 15;14(24):6107–6115.[PMC free article] [PubMed] [Google Scholar]
  • Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 1999 Jun;116(6):1453–1456. [PubMed] [Google Scholar]
Department of Oncology, Cambridge Institute for Medical Research and Strangeways Research Laboratories, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 2XY, UK.
Department of Oncology, Cambridge Institute for Medical Research and Strangeways Research Laboratories, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 2XY, UK.
Copyright notice

Abstract

Families with autosomal dominant inherited predisposition to gastric cancer have been described. More recently, germline E-cadherin/CDH1 mutations have been identified in hereditary diffuse gastric cancer kindred. The need to have protocols to manage and counsel these families in the clinic led a group of geneticists, gastroenterologists, surgeons, oncologists, pathologists, and molecular biologists to convene a workshop to produce consensus statements and guidelines for familial gastric cancer. Review of the available cancer pathology from people belonging to families with documented germline E-cadherin/CDH1 mutations confirmed that the gastric cancers were all of the diffuse type. Criteria to define the different types of familial gastric cancer syndromes were agreed. Foremost among these criteria was that review of histopathology should be part of the evaluation of any family with aggregation of gastric cancer cases. Guidelines for genetic testing and counselling in hereditary diffuse gastric cancer were produced. Finally, a proposed strategy for clinical management in families with high penetrance autosomal dominant predisposition to gastric cancer was defined.


Keywords: gastric cancer; familial; hereditary; E-cadherin

Abstract
Full Text
Selected References
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.